A development-stage pharma and medical device company focused on oncology, Delcath, is setting up its European headquarters in Galway, which will create jobs in marketing, sales and logistic support.
Backed by IDA Ireland, the new operation will support the US company’s commercial launch of its Hepatic Chemosat delivery system, which the company says may ultimately fulfil an annual unmet clinical need for as many as 100,000 patients with cancers in the liver across 30 European countries.
Recruitment is already under way for the Galway positions and the new headquarters is expected to be fully operational by the final quarter of this year.
“Galway is the European home for many international medical device and pharmaceutical companies attracted by its pro-business environment, efficient tax system, logistics and cost advantages, and deep pool of qualified management talent,” said Eamonn P Hobbs, president and CEO of Delcath System, Inc.
Barry O’Leary, CEO of IDA Ireland, said the life sciences sector was of paramount importance to foreign direct investment in Ireland and the establishment of this operation adds to the life sciences cluster that exists in Galway.
